NRIX

Nurix Therapeutics Inc

NRIX, USA

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

https://www.nurixtx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NRIX
stock
NRIX

Wells Fargo Raises Price Target for Nurix Therapeutics (NRIX) to $30 | NRIX Stock News GuruFocus

Read more →
NRIX
stock
NRIX

Nurix Therapeutics (NASDAQ:NRIX) Given New $30.00 Price Target at Wells Fargo & Company MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-08-31)

Rating:

BUY

Target Price:

$27.1765

Analyst Picks

Strong Buy

10

Buy

6

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bearish

Finn Analysis

(Last Updated 2025-08-31)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.18

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-23.22 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-16.54 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-761.29 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.40

Low 1

High 0.3

Investors

* Institutions hold a combined 118.27% of the total shares of Nurix Therapeutics Inc

1.

FMR Inc

(13.6593%)

since

2025/06/30

2.

BlackRock Inc

(8.9062%)

since

2025/06/30

3.

Deep Track Capital, LP

(7.9332%)

since

2025/06/30

4.

Vanguard Group Inc

(5.8411%)

since

2025/06/30

5.

COMMODORE CAPITAL LP

(5.1651%)

since

2025/06/30

6.

Baker Bros Advisors LP

(5.078%)

since

2025/06/30

7.

Redmile Group, LLC

(4.8828%)

since

2025/06/30

8.

Point72 Asset Management, L.P.

(4.8445%)

since

2025/06/30

9.

T. Rowe Price Associates, Inc.

(3.9684%)

since

2025/06/30

10.

State Street Corp

(3.3122%)

since

2025/06/30

11.

T. Rowe Price Investment Management,Inc.

(3.2361%)

since

2025/06/30

12.

Soleus Capital Management, L.P.

(3.1692%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(3.1599%)

since

2025/07/31

14.

Morgan Stanley - Brokerage Accounts

(2.8347%)

since

2025/06/30

15.

Vestal Point Capital LP

(2.6161%)

since

2025/06/30

16.

Pictet Asset Manangement SA

(2.6143%)

since

2025/06/30

17.

Geode Capital Management, LLC

(2.4617%)

since

2025/06/30

18.

iShares Russell 2000 ETF

(2.3772%)

since

2025/08/31

19.

Fidelity Select Health Care

(2.2106%)

since

2025/07/31

20.

UBS Group AG

(2.0786%)

since

2025/06/30

21.

Citadel Advisors Llc

(2.0785%)

since

2025/06/30

22.

ARK Investment Management LLC

(2.0602%)

since

2025/06/30

23.

ARK Genomic Revolution

(2.0081%)

since

2025/06/30

24.

ARK Genomic Revolution ETF

(2.0057%)

since

2025/08/28

25.

Wellington Management Company LLP

(1.9164%)

since

2025/06/30

26.

Amova ARK Pstv Chg Innovt P JPY Acc

(1.859%)

since

2025/07/31

27.

US Small-Cap Growth II Equity Comp

(1.7633%)

since

2025/06/30

28.

Strategic Advisers Fidelity US TtlStk

(1.3527%)

since

2025/07/31

29.

Fidelity Advisor Health Care I

(1.3081%)

since

2025/07/31

30.

T. Rowe Price New Horizons

(1.3076%)

since

2025/07/31

31.

Pictet-Biotech P USD

(1.2843%)

since

2025/05/31

32.

Fidelity Small Cap Growth

(1.2441%)

since

2025/06/30

33.

SPDR® S&P Biotech ETF

(1.2067%)

since

2025/08/31

34.

Fidelity Growth Compy Commingled Pl S

(1.0542%)

since

2025/07/31

35.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9943%)

since

2025/07/31

36.

Fidelity Small Cap Index

(0.9901%)

since

2025/06/30

37.

Pictet-Global Megatrend Sel I USD

(0.918%)

since

2025/05/31

38.

iShares Russell 2000 Value ETF

(0.8667%)

since

2025/08/31

39.

Fidelity Advisor Biotechnology I

(0.857%)

since

2025/07/31

40.

Fidelity Growth Company Fund

(0.8499%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-11-30

EPS Estimate

-0.8777

Latest Release

Date

2025-08-31

EPS Actual

-1.03

EPS Estimate

-0.8296

EPS Difference

-0.2004

Surprise Percent

-24.1562%

Investing Fit Scorecard

(Last Updated 2025-08-31)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-08-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-08-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-08-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.